BioNTech Results Presentation Deck
Status of COVID-19 vaccine program
Note: All future dates represented in graphic reflect anticipated timelines and
are subject to clinical, technical, regulatory and manufacturing success
SARS-CoV-2
Genetic
Sequence
Made public
January 12, 2020
Dijk
18
0000
Announced Collaborations
Fosun Pharma, March 16
Pfizer, March 17
ши
Initiated Project "Lightspeed"
Candidate selection
Animal Studies
Toxicology Studies
GMP manufacturing
Preliminary Data: BNT162b1
From Ongoing Phase 1 US trial, July 1
From Ongoing Phase 1 EU trial, July 20
Euro
Pivotal Phase 2b/3 Trial
with BNT162b2
First patient Dosed: July 27
Approximately 6 months to
initiate Pivotal Trial
Fast track designation for
BNT162b1 and BNT162b2
July 13
Phase 1/2 Trials ongoing in Europe, U.S. and in China (started later in July)
4 vaccine candidates in the clinic
> 500 subjects
=
Potential Filing
for Regulatory
Approval
or Emergency
Authorization
Goal: Q4 - as early
as October 2020
BIONTECHView entire presentation